Immunonkologie

Prof. Dr. Carsten Bokemeyer

Andre T et al. Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer. The phase 3 KEYNOTE-177 study.
Snow T et al. Characteristics and outcomes of real-world (RW) patients (pts) with microsatellite instability-high (MSI-H) solid tumors treated with Pembrolizumab monotherapy (P) after FDA approval.
Ghiringhelli F et al. Durvalumab and Tremelimumab in combination with FOLFOX in patients with RAS-mutated, microsatellite-stable, previously untreated metastatic colorectal cancer (MCRC): Results of the first intermediate analysis of the phase Ib/II MEDETREME trial.
Tanizaki J et al. NivoCUP: An open-label phase II study on the efficacy of nivolumab in cancer of unknown primary.

Prof. Dr. Sebastian Haen

Li W et al. Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± Tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure.
Alessi JVM et al. Outcomes to first-line Pembrolizumab in patients with PD-L1-high (≥50%) non-small-cell lung cancer and a poor performance status.
Kuruvilla J et al. KEYNOTE-204: Randomized, open-label, phase III study of Pembrolizumab (Pembro) versus Brentuximab Vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).
Powles T et al. Maintenance Avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.

Prof. Dr. Hendrik Poeck

Warner JL et al. Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19).
Horn L et al. Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival.

Immunonkologie Highlight

404 Not Found

Die Seite wurde leider nicht gefunden

Gründe dafür könnten sein, dass Sie eine falsche oder veraltete URL aufgerufen haben. Oder aber die Seite wurde von uns umbenannt, verschoben und archiviert. Versuchen Sie es noch einmal und aktualisieren Sie die Seite.

Andernfalls verwenden Sie bitte den folgenden Link, um die von Ihnen gewünschten Inhalte zu finden

Zur Startseite